Oppenheimer Analysts Give Teva Pharmaceutical Industries (NYSE:TEVA) a $12.00 Price Target

Oppenheimer set a $12.00 price objective on Teva Pharmaceutical Industries (NYSE:TEVA) in a research report sent to investors on Wednesday, TipRanks reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also weighed in on TEVA. Mizuho lowered shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating and lowered their target price for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. Citigroup lowered their target price on shares of Teva Pharmaceutical Industries from $27.00 to $23.00 and set a buy rating on the stock in a report on Thursday, April 11th. BMO Capital Markets started coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, March 28th. They issued a market perform rating and a $18.00 target price on the stock. Wells Fargo & Co reaffirmed a hold rating on shares of Teva Pharmaceutical Industries in a report on Friday, May 10th. Finally, Morgan Stanley set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Friday, May 3rd. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $17.05.

TEVA opened at $8.24 on Wednesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96. Teva Pharmaceutical Industries has a twelve month low of $8.19 and a twelve month high of $25.96. The stock has a market capitalization of $8.86 billion, a PE ratio of 2.94, a PEG ratio of 1.05 and a beta of 1.64.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.38 billion. During the same quarter in the prior year, the firm earned $0.94 EPS. The firm’s quarterly revenue was down 15.2% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current year.

In related news, Director Sol J. Barer purchased 111,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the transaction, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,860 shares of company stock worth $226,854. 0.49% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Kore Private Wealth LLC acquired a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $29,000. Coastal Investment Advisors Inc. acquired a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $37,000. Bruderman Asset Management LLC lifted its position in Teva Pharmaceutical Industries by 2,175.0% during the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after purchasing an additional 2,262 shares during the period. Lindbrook Capital LLC lifted its position in Teva Pharmaceutical Industries by 61.2% during the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after purchasing an additional 945 shares during the period. Finally, Cullen Frost Bankers Inc. acquired a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $40,000. Institutional investors and hedge funds own 65.10% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: What is the return on assets formula?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.